O	0	1	A
O	2	12	randomized
O	12	13	,
O	14	20	double
O	20	21	-
O	21	26	blind
O	26	27	,
O	28	34	active
O	35	42	control
O	42	43	,
O	44	55	multicenter
O	55	56	,
O	57	61	dose
O	61	62	-
O	62	69	finding
O	70	75	study
O	76	78	of
B-intervention	79	94	lipegfilgrastim
I-intervention	95	96	(
I-intervention	96	100	XM22
I-intervention	100	101	)
O	102	104	in
O	105	111	breast
O	112	118	cancer
O	119	127	patients
O	128	137	receiving
O	138	154	myelosuppressive
O	155	162	therapy
O	162	163	.

O	164	168	This
O	169	173	dose
O	173	174	-
O	174	181	ranging
O	182	187	study
O	188	191	was
O	192	201	conducted
O	202	204	to
O	205	213	identify
O	214	217	the
O	218	225	optimal
O	226	231	fixed
O	232	236	dose
O	237	239	of
O	240	255	lipegfilgrastim
O	256	264	compared
O	265	269	with
O	270	283	pegfilgrastim
O	284	285	6
O	285	286	.
O	286	287	0
O	288	290	mg
O	291	294	for
O	295	298	the
O	299	308	provision
O	309	311	of
O	312	322	neutrophil
O	323	330	support
O	331	337	during
O	338	354	myelosuppressive
O	355	367	chemotherapy
O	368	370	in
O	371	379	patients
O	380	384	with
O	385	391	breast
O	392	398	cancer
O	398	399	.

O	400	401	A
O	402	407	phase
O	408	409	2
O	410	415	study
O	416	419	was
O	420	429	conducted
O	430	432	in
O	433	438	which
B-total-participants	439	442	208
B-eligibility	443	455	chemotherapy
I-eligibility	455	456	-
I-eligibility	456	461	naive
I-eligibility	462	470	patients
O	471	475	were
O	476	486	randomized
O	487	489	to
O	490	497	receive
O	498	513	lipegfilgrastim
O	514	515	3
O	515	516	.
O	516	517	0
O	517	518	,
O	519	520	4
O	520	521	.
O	521	522	5
O	522	523	,
O	524	526	or
O	527	528	6
O	528	529	.
O	529	530	0
O	531	533	mg
O	534	536	or
B-control	537	550	pegfilgrastim
O	551	552	6
O	552	553	.
O	553	554	0
O	555	557	mg
O	557	558	.

O	559	564	Study
O	565	570	drugs
O	571	575	were
O	576	588	administered
O	589	591	as
O	592	593	a
O	594	600	single
O	601	613	subcutaneous
O	614	623	injection
O	624	626	on
O	627	630	day
O	631	632	2
O	633	635	of
O	636	640	each
O	641	653	chemotherapy
O	654	659	cycle
O	660	661	(
O	661	672	doxorubicin
O	672	673	/
O	673	682	docetaxel
O	683	685	on
O	686	689	day
O	690	691	1
O	692	695	for
O	696	700	four
O	701	702	3
O	702	703	-
O	703	707	week
O	708	714	cycles
O	714	715	)
O	715	716	.

O	717	720	The
O	721	728	primary
O	729	736	outcome
O	737	744	measure
O	745	748	was
B-outcome-Measure	749	757	duration
I-outcome-Measure	758	760	of
I-outcome-Measure	761	767	severe
I-outcome-Measure	768	779	neutropenia
I-outcome-Measure	780	781	(
I-outcome-Measure	781	784	DSN
I-outcome-Measure	784	785	)
I-outcome-Measure	786	788	in
I-outcome-Measure	789	794	cycle
I-outcome-Measure	795	796	1
O	796	797	.

O	798	806	Patients
O	807	814	treated
O	815	819	with
O	820	835	lipegfilgrastim
O	836	847	experienced
O	848	855	shorter
B-outcome	856	859	DSN
I-outcome	860	862	in
I-outcome	863	868	cycle
I-outcome	869	870	1
O	871	875	with
O	876	882	higher
O	883	888	doses
O	888	889	.

O	890	893	The
B-outcome	894	898	mean
I-outcome	899	902	DSN
O	903	906	was
B-iv-cont-mean	907	908	0
I-iv-cont-mean	908	909	.
I-iv-cont-mean	909	911	76
I-iv-cont-mean	912	916	days
O	917	919	in
O	920	923	the
O	924	939	lipegfilgrastim
O	940	941	6
O	941	942	.
O	942	943	0
O	943	944	-
O	944	946	mg
O	947	952	group
O	953	956	and
B-cv-cont-mean	957	958	0
I-cv-cont-mean	958	959	.
I-cv-cont-mean	959	961	87
I-cv-cont-mean	962	966	days
O	967	969	in
O	970	973	the
O	974	987	pegfilgrastim
O	988	989	6
O	989	990	.
O	990	991	0
O	991	992	-
O	992	994	mg
O	995	1000	group
O	1000	1001	,
O	1002	1006	with
O	1007	1009	no
O	1010	1021	significant
O	1022	1033	differences
O	1034	1041	between
O	1042	1051	treatment
O	1052	1058	groups
O	1058	1059	.

O	1060	1069	Treatment
O	1070	1074	with
O	1075	1090	lipegfilgrastim
O	1091	1092	6
O	1092	1093	.
O	1093	1094	0
O	1095	1097	mg
O	1098	1101	was
O	1102	1114	consistently
O	1115	1125	associated
O	1126	1130	with
O	1131	1132	a
O	1133	1139	higher
B-outcome	1140	1148	absolute
I-outcome	1149	1159	neutrophil
I-outcome	1160	1165	count
I-outcome	1166	1167	(
I-outcome	1167	1170	ANC
I-outcome	1170	1171	)
I-outcome	1172	1174	at
I-outcome	1175	1180	nadir
O	1180	1181	,
O	1182	1189	shorter
B-outcome	1190	1193	ANC
I-outcome	1194	1202	recovery
I-outcome	1203	1207	time
O	1207	1208	,
O	1209	1212	and
O	1213	1214	a
O	1215	1222	similar
B-outcome	1223	1229	safety
I-outcome	1230	1233	and
I-outcome	1234	1246	tolerability
I-outcome	1247	1254	profile
O	1255	1263	compared
O	1264	1268	with
O	1269	1282	pegfilgrastim
O	1282	1283	.

O	1284	1288	This
O	1289	1294	phase
O	1295	1296	2
O	1297	1302	study
O	1303	1315	demonstrated
O	1316	1320	that
O	1321	1336	lipegfilgrastim
O	1337	1338	6
O	1338	1339	.
O	1339	1340	0
O	1341	1343	mg
O	1344	1346	is
O	1347	1350	the
O	1351	1358	optimal
O	1359	1363	dose
O	1364	1367	for
O	1368	1376	patients
O	1377	1381	with
O	1382	1388	breast
O	1389	1395	cancer
O	1396	1399	and
O	1400	1408	provides
O	1409	1419	neutrophil
O	1420	1427	support
O	1428	1432	that
O	1433	1435	is
O	1436	1438	at
O	1439	1444	least
O	1445	1455	equivalent
O	1456	1458	to
O	1459	1462	the
O	1463	1471	standard
O	1472	1473	6
O	1473	1474	.
O	1474	1475	0
O	1475	1476	-
O	1476	1478	mg
O	1479	1484	fixed
O	1485	1489	dose
O	1490	1492	of
O	1493	1506	pegfilgrastim
O	1506	1507	.
